Abstract
Although the action of estrogens has been traditionally explained by the binding to and transactivation of the nuclear estrogen receptor (ER)α and ERβ, recently the G protein-coupled receptor GPR30/GPER has been involved in the rapid estrogen signaling. We investigated the ability of two original molecules, which were named GPER-L1 and GPERL2, to bind to and activate the GPER transduction pathway in cancer cells. Competition assays, docking simulations, transfection experiments, real-time PCR, immunoblotting, gene silencing technology and growth assays were performed to ascertain the selective action of GPER-L1 and GPER-L2 in activating the GPER-mediated signaling. Both compounds, which did not show any ability to bind to and activate the classical ERs, were able to bind to GPER and to trigger the rapid activation of the GPER/EGFR/ERK transduction pathway which led to the up-regulation of GPER-target genes. Notably, GPER-L1 and GPER-L2 induced the proliferation of SkBr3 breast and Ishikawa endometrial cancer cells at nM concentrations through GPER, hence providing further evidence on their capability to elicit relevant biological responses mediated by GPER. The identification and characterization of these novel compounds as selective GPER agonists represent a valuable tool to further dissect the pharmacology of this novel estrogen receptor and to better differentiate the specific functions elicited by each estrogen receptor subtype in cancer cells.
Keywords: Breast cancer cells, endometrial cancer cells, estrogen receptors, GPER-L1, GPER-L2, GPR30/GPER
Current Cancer Drug Targets
Title:Two Novel GPER Agonists Induce Gene Expression Changes and Growth Effects in Cancer Cells
Volume: 12 Issue: 5
Author(s): R. Lappano, C. Rosano, M. F. Santolla, M. Pupo, E. M. De Francesco, P. De Marco, M. Ponassi, A. Spallarossa, A. Ranise and M. Maggiolini
Affiliation:
Keywords: Breast cancer cells, endometrial cancer cells, estrogen receptors, GPER-L1, GPER-L2, GPR30/GPER
Abstract: Although the action of estrogens has been traditionally explained by the binding to and transactivation of the nuclear estrogen receptor (ER)α and ERβ, recently the G protein-coupled receptor GPR30/GPER has been involved in the rapid estrogen signaling. We investigated the ability of two original molecules, which were named GPER-L1 and GPERL2, to bind to and activate the GPER transduction pathway in cancer cells. Competition assays, docking simulations, transfection experiments, real-time PCR, immunoblotting, gene silencing technology and growth assays were performed to ascertain the selective action of GPER-L1 and GPER-L2 in activating the GPER-mediated signaling. Both compounds, which did not show any ability to bind to and activate the classical ERs, were able to bind to GPER and to trigger the rapid activation of the GPER/EGFR/ERK transduction pathway which led to the up-regulation of GPER-target genes. Notably, GPER-L1 and GPER-L2 induced the proliferation of SkBr3 breast and Ishikawa endometrial cancer cells at nM concentrations through GPER, hence providing further evidence on their capability to elicit relevant biological responses mediated by GPER. The identification and characterization of these novel compounds as selective GPER agonists represent a valuable tool to further dissect the pharmacology of this novel estrogen receptor and to better differentiate the specific functions elicited by each estrogen receptor subtype in cancer cells.
Export Options
About this article
Cite this article as:
Lappano R., Rosano C., F. Santolla M., Pupo M., M. De Francesco E., De Marco P., Ponassi M., Spallarossa A., Ranise A. and Maggiolini M., Two Novel GPER Agonists Induce Gene Expression Changes and Growth Effects in Cancer Cells, Current Cancer Drug Targets 2012; 12 (5) . https://dx.doi.org/10.2174/156800912800673284
DOI https://dx.doi.org/10.2174/156800912800673284 |
Print ISSN 1568-0096 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-5576 |
Call for Papers in Thematic Issues
Advances in Cancer Biomarkers and Potential Drug Targets: From Diagnosis to Therapy
Cancer biomarkers play a crucial role in the diagnosis, prognosis, and treatment of cancer. They provide valuable information for cancer detection, risk assessment, treatment selection, and monitoring response to therapy. With advancements in molecular biology and high-throughput technologies, there has been an increasing interest in identifying and characterizing cancer biomarkers ...read more
Novel Therapeutic Approaches to Target Drug Resistant Tumors
With the development of disciplines such as chemical biology and molecular biology, the genes or proteins closely related to tumor occurrence and development have gradually become clear. Targeted therapies targeting these genes or proteins provide more effective methods for tumor treatment. Tumor targeted drugs generally only act on specific targets ...read more
ROLE OF IMMUNE AND GENOTOXIC RESPONSE BIOMARKERS IN TUMOR MICROENVIRONMENT IN CANCER DIAGNOSIS AND TREATMENT
Biological biomarkers have been used in medical research as an indicator of a normal or abnormal process inside the body, or of a disease. Nowadays, various researchers are in process to explore and investigate the biological markers for the early assessment of cancer. DNA Damage response (DDR) pathways and immune ...read more
Targeting the battlefield between host and tumor: basic research and clinical practice on reshaping tumor immune microenvironment
Immune system protects host against malignant tumors through effector cells and molecules. Cancer development and its response to therapy are regulated by inflammation, which either promotes or suppresses cancer progression. Chronic inflammation facilitates cancer progression and treatment resistance, whereas induction of acute inflammatory reactions often lead to anti-cancer immune responses. ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Vascular Endothelial Growth Factor: A New Paradigm for Targeting Various Diseases
Current Angiogenesis (Discontinued) Meet Our Editorial Board Member:
Current Pharmaceutical Design Strategies that Target Tight Junctions for Enhanced Drug Delivery
Current Pharmaceutical Design Identification and Analysis of RNA Editing Events in Ovarian Serous Cystadenoma Using RNA-seq Data
Current Gene Therapy Polo-Like Kinases (Plks) are Prognostic Markers for Gynecologic Malignancies
Current Women`s Health Reviews Toxicity of Carbon Nanotubes
Current Drug Metabolism DNMT Inhibitors in Cancer, Current Treatments and Future Promising Approach: Inhibition of Specific DNMT-Including Complexes
Epigenetic Diagnosis & Therapy (Discontinued) Transcriptional Regulation as a Pharmacologic Intervention
Current Medicinal Chemistry - Immunology, Endocrine & Metabolic Agents Bisacylimidoselenocarbamates Cause G2/M Arrest Associated with the Modulation of CDK1 and Chk2 in Human Breast Cancer MCF-7 Cells
Current Medicinal Chemistry Leptin, Estrogens and Cancer
Mini-Reviews in Medicinal Chemistry Endothelial Progenitor Cells: A Vascular Perspective for Inflammatory Rheumatic Disorders
Current Rheumatology Reviews Safety of Systemic Biologic Agents in the Treatment of Non-malignant Skin Disorders
Current Drug Safety Endothelin-1 and Angiogenesis in Cancer
Current Vascular Pharmacology Pharmacological Modulation of Caspase Activation
Current Medicinal Chemistry - Anti-Inflammatory & Anti-Allergy Agents Gestational Trophoblastic Neoplasia, an Ancient Disease: New Light and Potential Therapeutic Targets
Anti-Cancer Agents in Medicinal Chemistry Heparanase as a Target in Cancer Therapy
Current Cancer Drug Targets Subcellular Imaging and Diagnosis of Cancer using Engineered Nanoparticles
Current Pharmaceutical Design Targeting Leptin as a Therapeutic Strategy against Ovarian Cancer Peritoneal Metastasis
Anti-Cancer Agents in Medicinal Chemistry The Possible Role of Infertility Drugs in Later Malignancy: A Review
Current Medicinal Chemistry Biomarkers for Risk Assessment and Prevention of Breast Cancer
Current Cancer Drug Targets